A urologic oncology roundtable discussion: the role of disease monitoring in treatment decision-making for patients with metastatic castration-resistant prostate cancer.

Shore ND, Concepcion R, Barocas DA
Hosp Pract (1995). 2013 41 (4): 78-80

PMID: 24145592 · DOI:10.3810/hp.2013.10.1083

A recent Elsevier survey of 200 urologists and oncologists who treat patients with castration-resistant prostate cancer (CRPC) identified a lack of physician confidence in understanding and using current clinical practices regarding the identification, treatment, and management of patients with CRPC. In response to this knowledge gap, a urologic oncology physician roundtable discussion was convened and a companion summary article created to provide a knowledge-based perspective for optimizing the identification, monitoring, and treatment of patients with metastatic CRPC (http://prostatecancer.urologiconcology.org/). Leading urology experts were selected to discuss how CRPC is defined and monitored, and to elaborate (through the presentation of 2 different cases) on considerations of how the currently approved chemotherapeutics, immunotherapy, and oral androgen inhibition agents can be used in the treatment of metastatic CRPC.

MeSH Terms (13)

Androstenols Antineoplastic Agents Cancer Vaccines Decision Making Drug Monitoring Humans Immunotherapy Male Medical Oncology Middle Aged Neoplasm Metastasis Practice Guidelines as Topic Prostatic Neoplasms, Castration-Resistant

Connections (1)

This publication is referenced by other Labnodes entities: